Company Description
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States.
The company’s cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.
It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment.
The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015.
PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Joshua Silverman |
Contact Details
Address: 3960 Howard Hughes Parkway, Suite 500 Las Vegas, Nevada 89169 United States | |
| Phone | 917 595 2850 |
| Website | pharmacyte.com |
Stock Details
| Ticker Symbol | PMCB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 1157075 |
| CUSIP Number | 71715X203 |
| ISIN Number | US71715X2036 |
| Employer ID | 62-1772151 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Joshua N. Silverman | Chief Executive Officer. President and Executive Chairman |
| Carlos A. Trujillo CPA | Chief Financial Officer |
| Dr. Jose L. Iglesias M.D. | Consulting Chief Medical Officer |
| Dr. Hans-Peter Hammes M.D. | Member of Medical and Scientific Advisory Board and Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Dec 18, 2025 | 10-Q | Quarterly Report |
| Dec 15, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Dec 5, 2025 | 8-K | Current Report |
| Nov 18, 2025 | 4 | Statement of changes in beneficial ownership of securities |
| Nov 18, 2025 | 8-K/A | [Amend] Current report |
| Nov 7, 2025 | SCHEDULE 13G/A | Filing |
| Oct 31, 2025 | 8-K | Current Report |
| Oct 6, 2025 | DEF 14A | Other definitive proxy statements |
| Sep 26, 2025 | EFFECT | Notice of Effectiveness |